Introduction
============

Total hip replacement (THR) is a very successful surgical procedure improving patients\' quality of life by providing pain relief and restoring function. However, a prosthetic joint infection (PJI) is a devastating complication occurring in 1-3% of patients after primary THR and 10-12% after revision procedures [@B1]. PJIs can be classified as early, delayed and late according to the time of symptom development after the index surgery [@B1]-[@B3]. Guidelines recommend to treat an early or hematogenous PJI with debridement, antibiotics and implant retention (DAIR). In general, a delayed or late infection is managed with either a one- or two-stage revision procedure combined with antibiotic treatment [@B4]. However, there are patients in which surgical strategies are contraindicated. This may be due to comorbidities, surgical conditions (e.g. poor bone stock) or patients\' refusal to undergo surgical therapy. For these patients, antibiotic suppressive therapy (AST) may be an alternative treatment option. The aim of this suppressive treatment is to control clinical manifestations of the infection rather than cure the infection [@B5].

Previous studies regarding AST in PJI are few. We have found a total of eight studies reporting clinical outcome of PJI patients treated with AST between 1988 and 2017 [@B6]-[@B13]. These studies included 13-92 patients treated with a variety of suppressive antibiotics, reporting success rates varying from 23% to 86% with a mean follow-up of 2-5 years. These studies on AST give us variable data on AST in mostly inhomogeneous groups with PJI of hip, knee, shoulder and elbow joints, different type, dosage and duration of antibiotic therapy with relatively short follow-up [@B6]-[@B13].

The aim of this study is to describe the clinical outcome of patients with a PJI after hip arthroplasty who received AST. Factors influencing their clinical outcome are investigated. In our hospital, AST is mainly applied after hip arthroplasty. In order to reach a homogenous group, only patients receiving AST after hip arthroplasty are included.

Materials and Methods
=====================

Study design and population
---------------------------

This retrospective cohort study was performed at the Radboud University Medical Centre in Nijmegen, the Netherlands. All patients with a PJI were discussed in a weekly multidisciplinary meeting with an orthopedic surgeon, an infection disease specialist and a microbiologist. All patients with a PJI in which treatment with AST was started between January 1, 2006 and December 31, 2013 were included. Follow-up was completed until October 31, 2018. PJI was diagnosed according to the MSIS criteria by means of 2 or more tissue cultures demonstrating growth of an identical pathogen or ≥1 cultured virulent micro-organism [@B14]. We also aimed to analyze the difference in success rate between patients treated with AST after DAIR, two-stage revision or PJI diagnosed after diagnostic puncture. The following data were collected from the patient files: general patient characteristics (age, gender, BMI, ASA classification, type of hip prosthesis, comorbidities), number of revision surgeries of the affected joint, time of onset of PJI, symptoms of PJI, causative microorganism, type, dosage and duration of AST and clinical and radiological outcome. We also collected laboratory results at the start of AST, i.e. C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR) and leucocyte count.

Antibiotic suppressive therapy
------------------------------

AST was defined as an oral antibiotic therapy without an end date, started with the intention to control the infection where curative treatment seems unachievable. The type and dosage were based on *in vitro* susceptibility of the cultured pathogens. Laboratory monitoring for potential toxicity and adverse events was performed.

Outcomes
--------

AST was considered to be successful in cases with retention of the prosthesis without clinical relapse of infection at final follow-up. In cases in which follow up had ended due to the death of the patient unrelated to (the treatment of) PJI, AST was considered successful. Failure was defined as death related to PJI or new surgical intervention at prosthesis side due to persistent or recurrent infection.

Follow-up
---------

Patients were seen at the outpatient clinic by the orthopedic surgeon or the infection specialist, every three months in the first year. The interval increased to yearly if there were no symptoms of PJI or adverse events due to antibiotics. Endpoints were (unrelated) death, re-intervention at prosthesis side due to infection or latest follow-up at outpatient clinic if no event occurred.

Statistical Analysis
--------------------

The statistical analysis was performed with IBM SPSS statistics, version 22.0 (IBM Corp., Armonk, N.Y., USA). To describe overall survival without an event, a Kaplan-Meier survival analysis was performed according to an intention-to-treat principle. To assess the association of risk factors, known from previous studies [@B8]-[@B13], with clinical outcome, a univariate logistic regression analysis was performed. In case off missing values these data were deleted from our analysis. P values \< .05 were considered to be statistically significant.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The local ethics committee has waived approval for this study.

Results
=======

A total of 23 patients (16 female) with a mean age of 70 years (range, 40-88 years) at start of their AST were included. Patient characteristics and medical history are shown in Table [1](#T1){ref-type="table"}. The majority of the patients (66.7%) had a PJI after previous revision surgery of the hip. The mean number of previous surgical procedures on the affected side was five operations (range 1-9). Indications for AST were surgical complexity with poor bone stock and severe soft tissue injury (29%), patients wish not to be re-operated (13%), poor general medical condition (21%). 9 patients (38%) had a combination of reasons (surgical complexity, poor general medical condition and/or patients wish not to be re-operated).

Surgical therapy
----------------

20 (87.5%) patients underwent surgery before the start of AST; 13 of these patients underwent DAIR of whom 5 patients were treated with gentamycin polymethylmethacrylate beads. During all DAIR operations, modular implant parts were exchanged and rinsing was performed with 3 liters of betadine-saline solution and 3 liters of normal saline. 7 patients underwent partial or total revision for suspected aseptic loosening or periprosthetic fracture with unexpected positive intraoperative cultures. The 3 (12.5%) patients without surgery underwent a sterile puncture of the hip under suspicion of a chronic PJI. Cultures proved a PJI in these patients who were in a poor medical condition/not suitable for operative treatment. The isolated microorganisms are stated in Table [2](#T2){ref-type="table"}.

Antibiotic therapy
------------------

All 20 (87.0%) patients who underwent surgery before the start of AST, initially received intended curative antibiotic therapy for a mean duration of 13.4 weeks (range 0.71-29.9 weeks). In 16 of these patients a rifampin-based combination therapy was given after surgery, in the remaining 4 patients AST was started shortly after surgical intervention.

In 14 patients (60.9%), AST was started immediately after the initial treatment. In 6 patients (26.1%) AST was started when they had a clinical relapse of their symptoms after an antibiotic-free period ranging from 3-24 weeks (mean 16 weeks) after their initial treatment. In 3 patients (12.5%) AST was started after positive sterile puncture of the hip, without initial curative therapy. The mean duration of the AST in our patient group was 38 months (range 1-151 months). The type, dosage and duration of the AST are summarized in Table [2](#T2){ref-type="table"}.

Results of AST
--------------

At time of final follow-up, AST was considered successful in 13 patients (56.5%) after a median follow-up of 33 months (range 1-151 months). Kaplan-Meier survival analysis estimates a mean symptom-free prosthesis retention period of 82 months (6.9 years) with a 95% confidence interval of 54-111 months. The Kaplan-Meier survival curve is shown in Figure [1](#F1){ref-type="fig"}. 9 patients (39.1%) had no event during follow-up. 4 patients (17.4%) died of causes unrelated to PJI. 2 of the 13 patients with a successful result ended the AST during follow-up and retained their prosthesis without any sign of infection at final follow-up.

AST failed in 10 patients (43.5%). 7 patients (29.2%) had a relapse of infection with the same micro-organism and 3 patients (13.0%) developed a new infection with a different micro-organism. One of the failures underwent a new surgical intervention (DAIR) after 6 months of AST. In 8 of the failed AST patients a Girdlestone procedure was performed of whom one patient underwent a reimplantation after 3 months. One of the failures underwent a proximal femur resection.

In this study 7 patients had a polymicrobial infection (30%), 6 patients had a Coagulase Negative Staphylococci (CoNS) infection (26%), 5 patients had a S. *aureus* infection (22%) and five infections were caused by other microorganisms (22%) (see Table [2](#T2){ref-type="table"}). The Kaplan Meier survival curve in Figure [2](#F2){ref-type="fig"} shows the survival of different PJI infections. Figure [3](#F3){ref-type="fig"} shows the Kaplan Meier survival curve of patients with a PJI with a S. *aureus* infection versus patients with PJI with a different microorganism. 4 out of 5 PJI caused by S. *aureus* failed (80.0%) versus 7 out of 19 failures (37.0%) in the patient group with an infection caused by other microorganisms. This difference however, was not significant (p=0.143). Figure [4](#F4){ref-type="fig"} shows the Kaplan Meier survival curve of patients who had an antibiotic-free period before the start of AST versus patients receiving AST directly after intended curative treatment. In 5 out of the 6 patients (83.3%) with an antibiotic-free period, treatment failed, versus 4 out of 14 failures (28.6%) in patients receiving AST directly after surgery (p=0.045). In the three patients with an assumed low-grade infection in which AST was started after puncture, one failure was observed. Figure [5](#F5){ref-type="fig"} shows the Kaplan Meier survival curve comparing patients who had a DAIR, one-stage revision or puncture before the start of AST. No significant difference was seen comparing these groups.

Table [3](#T3){ref-type="table"} shows the results of the univariate logistic regression analysis for variables that could possibly be associated with an increased failure rate. None of the variables were significantly associated with an increased risk of failure except for an antibiotic-free period before the initiation of AST.

There were 4 patients in which follow up ended before 6 months of AST. Two of these patients had a clinical relapse of PJI and were marked as failures. One patient died of a cardiac cause unrelated to PJI treatment and the other patient stopped AST due to side effects but retained his prosthesis until final follow up. We separately analyzed patients receiving at least 6 months of AST showing a success rate of 63.2% (12 out of 19 patients).

Adverse events
--------------

6 (26.1%) patients experienced adverse events during AST. 4 of these patients experienced gastrointestinal problems, a rash or itching but could continue suppressive treatment; in 2 of these patients the dosage was reduced, in another patient cotrimoxazole was switched to doxycycline and 1 patient experienced a temporary itching sensation without the need to change or stop the AST. The other 2 patients (8.7%) ended their therapy due to adverse events. 1 of them was suspected to have pleural effusion as an adverse event; further analysis however did not confirm this. The other patient had to end the suppressive therapy due to thrombocytopenia during the use of Doxycycline in combination with TAR syndrome (thrombocytopenia-absent radius syndrome).

Discussion
==========

AST is suggested to be an alternative treatment in selected patients with a PJI in which further surgical intervention is unattractive. The aim of this study was to describe the clinical outcome of patients treated with AST in PJI after hip arthroplasty.

We found a 56.5% success rate after a median follow-up of 33 months. Considering an estimated mean survival of 82 months (95% CI 54-111), AST appears to be a rational treatment option when curative treatment seems impossible. Success rate in previous studies vary from 23 to 86% [@B6]-[@B13]. Table [4](#T4){ref-type="table"} summarizes the results of previous studies reporting on AST [@B8]-[@B13]. The presented studies in Table [4](#T4){ref-type="table"} included a wide variety of PJI including infections of total hip, knee, elbow and shoulder prosthesis. Both Siquira et al and Pradier et al found that infection involving the hip joint was associated with a better outcome compared to other PJIs [@B11], [@B13]. To be able to give a fair impression of what to expect from AST after hip surgery, solely PJI after hip arthroplasty were included.

Siqueira et al was the first study comparing 92 patients treated with AST for PJI with a matched cohort of patients with PJI not receiving AST (ratio 3:1) [@B11]. They found a significant difference in five-year infection-free prosthetic survival rate of 68.5% in the AST group compared to 41.1% in the non-suppression group. Interestingly, they found a greater benefit from AST in patients with a S.*aureus* infection compared to patients with a S.*aureus* infection not treated with AST.

In other previously published literature, several variables associated with a lower chance of survival are described; S.*aureus* infection [@B8], [@B9], [@B10], [@B12], older age (\>85 years), female gender, hypoalbuminemia, presence of a sinus tract [@B10], tumor prosthesis, higher level of inflammation blood values, rheumatoid arthritis [@B12], longer initial curative treatment and discontinuation of AST after 2 years [@B13]. We performed a univariate logistic regression analysis for all of these variables as described in Table [3](#T3){ref-type="table"}. In accordance with other studies we found a higher failure rate among PJI caused by S. *aureus* (80% versus 37%). However, this difference is not statistically significant. Consistent with the findings of Wouthuyzen et al [@B12], we found a higher failure rate among patients with higher inflammatory parameter; 60% of the patients with a CRP level ≥ 80ml/L failed, versus 20% of the patients with a CRP level \< 80ml/L at the start of AST. In our study, this difference was not statistically significant (p=0.79). Interestingly, we did find one statistically significant variable in this study. We have included 6 patients who had an antibiotic-free period before AST was started. In these patients PJI relapsed after initial curative treatment. In 5 of these patients (83.3%) AST failed versus 4 out of 14 failures (28.6%) in patients receiving AST directly after initial curative treatment (p=0.045). Despite no multivariate regression analysis could be performed, this finding suggests that AST should only be started when followed directly after curative antibiotic treatment and that bacterial load reduction seems essential for AST to be successful. However, the lower success rate in this subgroup of patients could also be explained by the fact that these patients already have shown a relapse of PJI at the start of AST. The inclusion of these patients could possibly explain a lower success rate in our study compared to previous studies described in table [4](#T4){ref-type="table"} [@B8],[@B9],[@B11]-[@B13].

Strengths of this study
-----------------------

This is the first study on AST solely describing patients with a PJI after hip replacement. An intention-intention-to-treat analysis gives a fair impression of what to expect when considering AST in PJI treatment after hip arthroplasty. All patients had a microbiologically proven PJI, the microorganism was susceptible to oral antibiotic therapy, and the type of antibiotic therapy was based on *in vitro* susceptibility of the pathogen. Almost all of our patients used either doxycycline or cotrimoxazole.

The optimal regimen and duration of AST remains uncertain. We generally prescribed doxycycline 100 mg q.d. and cotrimoxazole 480-960 mg q.d. This is half of the recommended dosages of doxycycline 100 mg b.i.d. and cotrimoxazole 960 mg b.i.d., as described in the IDSA guidelines [@B4]. Especially in patients who are treated with AST because of their medical condition, a low dosage of antibiotics is favored because of the possible side effects. Only two patients (8.7%) had to end their antibiotic therapy due to adverse events. Rao et al. showed a similar percentage of 8% [@B9]. In the patient group presented by Segreti et al. 22% percent of the patients showed adverse events [@B8].

Study limitations
-----------------

As in previously performed studies on AST, the retrospective design and low number of patients are the main limitations of our study. Because of the small sample size, a multivariate analysis with Cox-regression analysis could not be performed to assess variables associated with an increased risk of treatment failure. A third limitation of this study is the use of different initial treatment regimens.

Conclusion
==========

AST may be the only treatment option in patients in which curative treatment with surgical intervention is contraindicated. In addition to previous literature, this study suggests the use of chronic suppressive antibiotics is safe with acceptable outcomes, considering the absence of alternative treatment strategies. When considering the start of AST, one should be aware of a possible decreased success rate among patients who had an antibiotic-free period before the start of AST, patients with high inflammatory parameters and S. *aureus* infections.

Due to the small sample size and inhomogeneous study group in the current and previous studies, we have not been able to identify definite risk factors for failure of AST. Therefore, recommendation on the use of AST in the current international guidelines remains based on the few available data and expert opinions. Ideally, a prospective randomized controlled trial with larger numbers is performed to assess the optimal regimen and safety of antibiotic suppressive treatment. However, this seems an unachievable goal given the exceptional inhomogeneous group of patients and lack of alternative treatment options. Therefore, we emphasize a systematic review of the currently available studies is necessary to facilitate the development of guidelines for routine practice.
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AST

:   Antibiotic suppressive therapy

PJI

:   Prosthetic joint infection

CoNS

:   Coagulase Negative Staphylococci

S. *aureus*

:   Staphylococcus aureus

THR

:   Total hip replacement

MSIS

:   Musculoskeletal infection society

BMI

:   Body mass index

ASA

:   American society of anesthesiologists

CRP

:   C-reactive protein

ESR

:   Erythrocyte sedimentation rate

q.d.

:   once daily

b.i.d.

:   twice daily

IDSA

:   Infectious Diseases Society of America
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###### 

Patient characteristics of 23 patients with PJI treated with antibiotic suppressive therapy

  Characteristics                                               Number of patients
  ------------------------------------------------------------- --------------------
  **Gender**                                                    
  Female, n (%)                                                 16 (69.6)
  **Age at start AST, years, mean (range)**                     70 (40-88)
  **BMI, kg/m², mean (range)**                                  26.6 (16.8-44.8)
  **BMI group, n (%)**                                          
  \<20                                                          4 (17.4)
  20-25                                                         6 (26.1)
  25-30                                                         7 (30.4)
  30-35                                                         5 (21.7)
  \>35                                                          1 (4.3)
  **ASA score, n (%)**                                          
  1                                                             3 (13.0)
  2                                                             12 (52.2)
  3                                                             8 (34.7)
  **Co-morbidity**                                              
  Cardiovascular                                                9 (39.1)
  Rheumatoid arthritis                                          1 (4.3)
  Diabetes mellitus type 2                                      2 (8.7)
  Malignancy \<5 years                                          3 (13.0)
  **Prosthetic joint, n (%)**                                   
  Total hip arthroplasty                                        21 (91.3)
  Hemi arthroplasty                                             2 (8.7)
  **Arthroplasty, n (%)**                                       
  Primary implant                                               4 (17.4)
  Revised implant                                               19 (82.6)
  **Type/onset of PJI, n (%)**                                  
  Early (\<3 months)                                            7 (30.4)
  Delayed (3-24 months)                                         8 (34.7)
  Late (\>24 months)                                            8 (34.7)
  **Previous PJI, n (%)**                                       
  Yes                                                           9 (39.1)
  **DAIR**                                                      
  Yes                                                           13 (56.5)
  1 x DAIR                                                      8
  2 x DAIR                                                      3
  3 x DAIR                                                      1
  4 x DAIR                                                      1
  **Physical examination at time of PJI symptoms, n (%)**       
  Fever                                                         5 (21.7)
  Sinus tract                                                   5 (21.7)
  **Laboratory examination at time of PJI symptoms, n (%)**     
  Elevated CRP (\>10 mg/l)                                      19 (82.6)
  Elevated total leukocyte count (\>11.0 x10^9^/l)              5 (21.7)
  **Radiological examination at time of PJI symptoms, n (%)**   
  Loosening of the cup                                          2 (8.7)
  Radiolucency of the cup                                       2 (8.7)
  Protrusion of hemi arthroplasty with radiolucency stem        2 (8.7)
  Broken osteosynthesis material                                1 (4.3)

AST: antibiotic suppressive therapy; BMI: body mass index; ASA: American Society of Anesthesiologists; DAIR: Debridement, Antibiotics and Implant Retention.

###### 

Identified microorganisms and agents, dosages and duration of the used antibiotic suppressive therapy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient no.   Microorganism(s)                         Type and dosage of AST                                                   Time on AST (months)   Comments/adverse effects                                                     Outcome
  ------------- ---------------------------------------- ------------------------------------------------------------------------ ---------------------- ---------------------------------------------------------------------------- ---------
  1             EC, CoNS                                 Cotrimoxazole 480 mg q.d                                                 87                     No doxycycline because usage of methotrexate                                 success

  2             CoNS                                     Doxycycline 100 mg q.d                                                   33                                                                                                  failure

  3             Clostridium perfringens                  Doxycycline 100 mg q.dRifampin 300 mg b.i.d                              67                     Lower dosage because of nausea and dry mouth                                 success

  4             CoNS, GBS                                Cotrimoxazole 480 mg b.i.d Amoxicillin 500 mg t.i.d                      19                                                                                                  failure

  5             SA, PA                                   Doxycycline 100 mg q.d                                                   62                                                                                                  success

  6             SA                                       Doxycycline 100 mg q.d                                                   36                                                                                                  failure

  7             CA                                       Cotrimoxazole 480 mg q.d                                                 7                      Discontinuation because of possible toxicity (pleural effusion)              success

  8             CoNS                                     Doxycycline 100 mg q.d                                                   33                                                                                                  success

  9             CoNS                                     Cotrimoxazole 960 mg q.d (3 months) followed by doxycycline 100 mg q.d   16                     Switch to doxycycline because of nausea                                      failure

  10            CoNS                                     Doxycycline 100 mg q.d                                                   20                     Lower dosage because of nausea                                               success

  11            CoNS                                     Doxycycline 100 mg q.d                                                   15                                                                                                  failure

  12            SA                                       Ciprofloxacin 500 mg b.i.d                                               8                                                                                                   failure

  13            SA, CoNS                                 Doxycycline 100 mg q.d                                                   6                                                                                                   failure

  14            SA, CoNS                                 Doxycycline 200 mg q.d                                                   28                                                                                                  failure

  15            CoNS, corynebacterium                    Doxycycline 100 mg q.d                                                   3                      Discontinuation because of thrombocytopenia in patient with TAR syndrome\*   success

  16            CoNS                                     Doxycycline 100 mg q.d                                                   69                                                                                                  success

  17            Proteus Mirabilis, EF, corynebacterium   Amoxicillin-clavulanate 625 mg t.i.d.                                    1                                                                                                   failure

  18            CoNS                                     Doxycycline 200 mg q.d                                                   5                      Itching sensation but continued treatment                                    failure

  19            Pseudomonas, CoNS                        Doxycycline 200 mg q.d\                                                  5                                                                                                   success
                                                         Ciprofloxacin 750 mg b.i.d                                                                                                                                                   

  20            CoNS, EF                                 Amoxicillin-clavulanate 625 mg t.i.d                                     20                                                                                                  success

  21            CA                                       Cotrimoxazole 960 mg q.d                                                 68                                                                                                  success

  22            Gram-positive rods                       Doxycycline 100 mg q.d.                                                  109                                                                                                 success

  23            Serratia Marcescens                      Cotrimoxazole 960 mg b.i.d                                               151                                                                                                 success
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EC: Enterobacter clocae; EF: Enterococcus faecalis; CA: Cutibacterium acnes; SA: Staphylococcus aureus; SE: Staphylococcus epidermidis; CoNS: coagulase-negative Staphylococci; GBS: group B Streptococci.

q.d: once a day; b.i.d.: twice daily; t.i.d.: three times daily; q.i.d.: four times daily.

\* TAR syndrome = Thrombocytopenia Absent Radius syndrome

###### 

Univariate regression analysis

  Variables                    n    Failures (%)   Odds ratio for success (95% CI)   p-valueᵃ
  ---------------------------- ---- -------------- --------------------------------- ----------
  **Gender**                                                                         
  Male                         7    3 (42.9%)                                        
  Female                       16   7 (43.8%)      1.04 (0.17-6.23)                  0.968
  **Age**                                                                            
  \<50                         4    1 (25.0%)                                        
  50-70                        8    4 (50.0%)                                        
  \>70                         11   5 (45.5%)                                        0.713
  **ASA score**                                                                      
  1                            3    1 (33.3%)                                        
  2                            12   7 (58.3%)                                        
  3                            8    2 (25.0%)                                        0.331
  **Sinus tract**                                                                    
  Not present                  19   9 (47.4%)                                        
  Present                      4    1 (25.0%)      2.70 (0.24-30.85.)                0.424
  **Microbiology**                                                                   
  CoNS                         6    3 (50.0%)                                        
  S. Aureus                    5    4 (80.0%)                                        
  Other                        5    0 (0.00%)                                        
  Polymicrobial                7    3 (42.9%)                                        0\. 663
  **BMI**                                                                            
  \<30                         17   8 (47.1%)                                        
  \>30                         6    2 (33.3%)      1.78 (0.25-12.45)                 0.562
  **Arthroplasty**                                                                   
  Primary implant              4    1 (25.0%)                                        
  Revised implant              19   9 (47.4%)      0.37 (0.03-4.23)                  0.424
  **Type/onset of PJI**                                                              
  Early                        7    4 (57.1%)                                        
  Delayed                      8    3 (37.5%)                                        
  Late                         8    3 (37.5%)                                        0.687
  **CRP (3 missing values)**                                                         
  \<80                         10   2 (20.0%)                                        
  ≥80                          10   6 (60.0%)      6.00 (0.81-44.35)                 0.079
  **Initial treatment**                                                              
  DAIR                         13   6 (46.2%)                                        
  Revision                     7    3 (42.9%)                                        
  Puncture                     3    1 (33.3%)                                        0.533
  **Duration of AST**                                                                
  AST \<6 months               4    2 (50.0%)                                        
  AST ≥6 months                19   8 (42.1%)      1.375 (0.158-11.937)              0.773
  **AB free period**                                                                 
  Yes                          6    5 (83.3)       0.080 (0.007-0.918)               0.042
  None                         14   4 (28.6)                                         
  Puncture                     3    1 (33.3%)                                        

RA: rheumatoid arthritis; DM: diabetes mellitus; PJI: prosthetic joint infection; ASA: American Society of Anesthesiologists; BMI: body mass index.

ᵃ = log rank test

###### 

Previous studies on AST in PJI

  Author                           Year and Journal of publication   Number of patients   Mean follow-up (years)   Success rate (%)
  -------------------------------- --------------------------------- -------------------- ------------------------ ------------------
  Goulet et al [@B6]               1988, J. Arthroplasty             19                   4.1                      63.0
  Tsukayama et al [@B7]            1991, J. Orthopedics              13                   3.1                      23.0
  Segreti et al [@B8]              1998, Clin Inf Disease            18                   4.1                      83.0
  Rao et al [@B9]                  2003, CORR                        36                   4.4                      86.2
  Prendki et al [@B10]             2014, Int J Inf Disease           38                   2.0                      60.0
  Siqueira et al [@B11]            2015, J Bone Joint Surg Am.       92                   5.8                      68.5
  Wouthuyzen-Bakker et al [@B12]   2017, J Bone Joint Infect         21                   1.8                      67.0
  Pradier et al [@B13]             2018, Infection                   78                   2.8                      71.8
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